"MENLO PARK, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq:GERN - News) today announced that data show GRNOPC1, the company’s human embryonic stem cell (hESC)-based therapeutic for spinal cord injury, survives and exhibits durable and robust human remyelination in spinal cord-injured rats for at least nine months following a single injection.
Presented by Geron’s Arjun Natesan, Ph.D., at the Society for Neurosciences Annual Meeting in San Diego, the data also demonstrate that GRNOPC1 does not amplify neuropathic pain or the reaction to painful stimuli. This finding is in contrast to research that shows many other cell types, when injected into the spinal cord, amplify neuropathic pain, a common long-term complication of spinal cord injury in man."
Note: Remyelination is the regeneration of the protective part of the nerve called the myelin sheath.
To view this entire article, please click the title above.
No comments:
Post a Comment